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Abstract 
Background: Malaria the first causes of death from parasitic infection worldwide. Interventions to reduce the burden 
of malaria have produced a tremendous drop in malaria morbidity and mortality. However, progress is slower in DRC, 
which shares with Nigeria 39% of deaths related to malaria globally. Inappropriate use of drugs may be one of the fac‑
tors of this below‑average performance. The aim of this study was to describe the use of drugs in the management of 
uncomplicated malaria in public health facilities in DRC.
Methods: A drug use study was carried out in DRC from January to March 2014. In each of the former 11 provinces 
of DRC, one Rural Health Centre, one Urban Health Centre and one General Hospital were selected. In each of them, 
100 patient’s files containing prescription of anti‑malarials from January to December 2013 were randomly selected. 
Among them, all of the files with diagnosis of uncomplicated malaria were included in this study. Prescribed anti‑
malarials, co‑prescribed drugs and their indications were collected. Descriptive analyses were performed.
Results: A total of 2300 files out of 3300 (69.7%) concerned uncomplicated malaria and were included in analy‑
sis. Malaria treatment was initiated after a positive RDT or microscopy in 51.5% of cases, upon suspicion without 
requesting biological confirmation in 37% and despite negative results in 11%. Twenty‑nine (29) different treatment 
regimens were used. The drugs recommended by the National Malaria Control Programme were used in 54.3% of 
cases (artesunate–amodiaquine 37.4% or artemether–lumefantrine 16.9%). The second most used anti‑malarial was 
quinine (32.4%). Apart from anti‑malarials, an average of 3.1 drugs per patient were prescribed, among which antibiot‑
ics (67.9%), analgesics and non‑steroidal anti‑inflammatory (NSAIDs) (all abbreviations to be explicated on first use) 
(70.6%), vitamins (29.1%), anaemia drugs, including blood transfusion (9.1%) and corticosteroids (5.7%), In 51.4% of 
cases there was no indication for the concomitant medication.
Conclusion: Management of uncomplicated malaria in DRC is characterized by a low adherence to treatment policy, 
numerous treatment regimens, and abundant concomitant medication potentially harmful to the patient. This may 
contribute to the low performance of DRC in malaria control. Determinant of this irrational use of drugs need to be 
assessed in order to formulate and implement efficient corrective measures.
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Background
Malaria is the first cause of death from parasitic infection 
worldwide. Developing tropical countries are the most 
affected. There were about 212 million cases of malaria in 
2015 and an estimated 429,000 deaths among which 90% 
lived in the African region [1]. In the Democratic Repub-
lic of the Congo (DRC), 97% of the population is at risk 
of endemic malaria and the remaining 3% is exposed to 
malaria epidemics.
Fighting malaria involves many organizations at inter-
national and national level and the disease was included 
in the Millennium Development Goal (MDG 6c); which 
was to halt and begin to reverse the incidence of malaria 
by 2015 [2]. In 2005, the World Health Assembly (WHA) 
set the targets of reducing malaria case incidence rates 
by 75% by 2015 [2, 3]. As a result, the average malaria 
infection prevalence declined by 48% in children aged 
2–10  years, mortality decreased by 47% worldwide and 
by 54% in the World Health Organization (WHO) Africa 
Region between 2000 and 2015, and 55 countries met the 
target set by the MDGs [1]. However, DRC is not on track 
to achieve the MDG or WHA targets; instead, it is among 
the 13 countries that carry 78% of the burden of malaria 
and in which the reduction of malaria incidence of 32% 
since 2000 is below the average of 53% in the other coun-
tries globally [2]. With about 1% of the world population 
[3] and 1.7% of those exposed to malaria, DRC had 9% 
of malaria cases and 10% of malaria deaths in 2015 and 
together with Nigeria a share of 36% of deaths related to 
malaria globally [1]. Inappropriate use of drugs may be 
among the determinants of this counter performance.
Inappropriate use of anti-malarials [4, 6], poor adher-
ence to treatment guidelines [5, 7], lack of laboratory data 
supporting diagnosis of malaria before treatment [6, 8] 
or usage of drugs known to be ineffective [7] have been 
reported from African countries affected with malaria. 
In addition to anti-malarials, other drugs e.g., antibiotics, 
are irrationally used during malaria treatment [8, 10]. In 
DRC, an unpublished study of Mesia et al. found that the 
recommended ACT was only used by 6% of healthcare 
providers three years after implementation of artesunate/
amodiaquine as first-line treatment for uncomplicated 
malaria. The situation had not changed much in 2014: 6% 
of children under 5 years with fever received an ACT [9].
There is an apparent need to improve rational use of 
anti-malarials, but without a knowledge basis of how 
drugs are being prescribed and used, it is difficult to initi-
ate a discussion on rational drug use or to suggest meas-
ures to improve prescribing habits [10]. Taking this into 
account, it is of paramount importance to first assess the 
current practices in the use of anti-malarial drugs. The 
aim of this study is to describe the prescription of drugs 
in the management of uncomplicated malaria in Public 
Health facilities in DRC.
Methods
Study setting
DRC is the second largest and the fourth most popu-
lated country of Africa with a population estimated to 
81 million inhabitants [11] The health system of DRC is 
composed of 515 Health Zones, each of them compris-
ing one General Referral Hospital (GRH) and several 
Health Centres (HC). Most of them are integrated in 
the national health system and thus connected to the 
National Malaria Control Programme. Current, treat-
ment policy of malaria in DRC [12] recommends that 
uncomplicated malaria is to be managed in HC, while 
severe malaria is managed in Referral Hospitals. HC are 
rural or urban according to their geographical location: 
rural areas are characterized by more poverty, less quali-
fied health personnel, difficulties in transportation and 
all social services. Urban areas are characterized by more 
qualified health personnel, some better social services, 
but also more promiscuity. HC are mostly run by nurses 
especially in rural areas; physicians may sometimes be 
found in urban health centres but are mostly responsible 
of patient care in GRH. The study was carried out in all 
the previous 11 provinces of DRC. In each one of them, 
one GRH, one rural HC and one urban HC were selected 
to capture use of drugs in complicated, in uncomplicated 
malaria, as well as urban and rural conditions. DRC has 
been through many civil wars and there are still armed 
groups in many remote areas especially in the eastern 
regions. Therefore, the study was conducted in the Capi-
tal cities and the surrounding rural areas in each prov-
ince. This is also where the population fleeing the abuses 
of the armed groups converge. The total catchment area 
covered by these health facility is approximately 4.5 mil-
lion inhabitants according to the date provided by the 
Health Zones. The recommended drugs for uncompli-
cated malaria are artesunate + amodiaquine (ASAQ) or 
artemether + lumefantrine (AL).
Study design
This was a cross-sectional drug use study that aimed at 
assessing the prescription of anti-malarial drugs. There-
fore, a retrospective review of patients’ file containing a 
prescription of an anti-malarial from January to Decem-
ber 2013 was performed. One hundred files were ran-
domly selected in each health facility as recommended by 
WHO in the investigation about drug use in health facili-
ties [13], yielding a sample size of 3300 files. The data 
were collected from January to March 2014. Patients’ 
files were thereafter classified according to the diagno-
sis of malaria recorded by the prescriber: uncomplicated 
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malaria, treatment failure, severe malaria, and are kept 
electronically as Excel spreadsheets.
Only the patients’ file in which the indication of anti-
malarial prescription was uncomplicated malaria were 
included in this study. All cases of severe malaria or no 
malaria diagnosis were excluded from the analysis. For 
each of them, the following variables were recorded: 
Province, health facility (GRH, urban HC or Rural HC), 
age, and medical history; clinical signs and symptoms 
as well as laboratory results supporting the diagnosis of 
malaria; and the drug prescribed (anti-malarials and co-
prescribed medication with their indication). Data were 
entered using Epi-info 7, CDC Atlanta, then exported 
in Microsoft Excel 2013. Descriptive analyses were per-
formed. Calculation of 95% confidence interval was per-
formed using Stata 12.
Statistical analysis
Descriptive analyses were performed. Calculation of 
95% confidence interval was performed using Stata 12.0 
(StataCorp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: StataCorp).
Variables were described by count or frequencies. 
When necessary, Chi square tests was used to com-
pare them in children less than 5  years old with other 
patients. A p value < 0.05% was considered for statistical 
significance.
Results
This drug use study was conducted in the 11 former 
provinces of DRC and analysed the patterns of the pre-
scription of anti-malarial drugs in Health Centres and 
General Referral Hospitals. Of the 3300 patients’ files col-
lected 2300 had uncomplicated malaria as the indication 
for anti-malarial drug prescription Tables 1 and 2.
Patients’ characteristics
About one-third of the patients (37.9% of cases) are chil-
dren under 5 years of age. Among them, 6.3% (140/2227) 
were less than 6 months old.
Medical management
Confirmation of diagnosis prior to initiation of treatment
Confirmation of malaria by rapid diagnostic test (RDT) 
or microscopy was requested by the medical person-
nel only in 63% (1436/2300) of suspected cases; in 
52% (1184/2300), the results were positive and in 11% 
(252/2300) of cases, malaria treatment was initiated 
despite negative results. In 2.6% of cases (59/2300), 
malaria diagnosis was based on both microscopy and 
RDT. Both were positive in 48 patients; in 11 cases, 
microscopy was positive but RDT negative. Table  3 
shows that prescription of anti-malarial was based more 
frequently on positive results in children blow 5 years old.
Medical management of uncomplicated malaria
A total of 29 different treatments were used to man-
age uncomplicated malaria. The most used drugs were 
ASAQ, AL and quinine. As shown in Table 4 they were 
prescribed to 1994 patients (86.7%). They are are followed 
by the injectable artemisinin derivatives, alpha–beta 
arteether and artemether, then sulfadoxine-pyrimeth-
amine (SP). The other drugs represented together 3.7%; 
each of them was used in less than 1% of patients. They 
include quinine containing treatments (quinine plus 
ACT, such as ASAQ, AL, dihydroartemisinin–pipe-
raquine (DHA–PQ), quinine plus doxycycline, SP, 
artemether or artesunate); other ACT medicines, such 
as DHA–PQ and artesunate-SP and oral monotherapies, 
including oral artemisinin-based monotherapy (oAMT). 
Quinine and ASAQ were significantly more used in the 
Table 1 Age group (n = 2227)
Age group (year) Number (%)
< 5 845 (37.9)
5–13 401 (18.0)
14–18 156 (7.0)
19–64 785 (35.3)
≥ 65 40 (1.8)
Table 2 Biological confirmation of malaria
Result of biological examination Number % 95% CI
Positive microscopy or RDT 1184 51.5 49.4–53.5
Negative microscopy or RDT 252 11.0 9.7–12.3
None 853 37.0 35.1–39.1
Positive microscopy, negative RDT 11 0.5 0.2–0.9
Total 2300 100
Table 3 Biological confirmation in  children under  5  years 
old compared to other patients
Result of biological 
examination
< 5 years, 
number 
(%)
N = 845
≥ 5 years, 
number 
(%)
N = 1455
p value
Positive microscopy or RDT 464 (54.9) 720 (49.5) 0.012058
Negative microscopy or RDT 79 (9.3) 173 (11.9) 0.059995
None 296 (35.0) 557 (38.2) 0.119552
Negative RDT positive microscopy 6 (0.7) 5 (0.3)
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subgroup of under 5 years old children the most affected 
by malaria whereas, artemether–lumefantrine and the 
injectable artemisinin derivative alpha–beta arteether 
were more used in the patients aged 5  years old and 
above.
Concomitant medication
Fifty-six patients (2.4%) received no other drug than anti-
malarials. The other patient received an average of 3.1 
drugs. Table 5 shows, for every concomitant medication, 
the number of patients that received it. Analgesics and 
NSAIDs were the most prescribed, to 70.6% of patients; 
antibiotics were prescribed to 68% of patients. Vita-
mins were prescribed to 29% of patients and the other 
anti-infectious drugs, mostly anti-helminthics were pre-
scribed in 27.5% of cases. Antibiotics were used without 
a specified diagnosis in 56.2% of cases and for a non-bac-
terial infectious condition (vomiting, intestinal parasito-
sis, flu) in 16.6% of cases. Among antalgics, metamizole, a 
drug with known serious haematologic adverse reactions 
was prescribed to 12.2% of patients. Drug combinations 
used in influenza were prescribed to 6.1% of patients.  
All age groups received concomitant medication. 
Table 6 shows that, significantly more children under five 
were prescribed antibiotics compared to other patients 
(75% vs. 63%). Antalgics, (74.7% vs. 68.3%), drugs used 
for anaemia, among which, iron salts, folate and vitamin 
B12 and blood transfusion (16.2% vs. 4.9%). Ten of the 
11 blood transfusions were given to children of this age 
group. For the one remaining transfusion, age was not 
specified but the weight of the patient (8.5  kg) strongly 
suggests he is in this same age group. Corticosteroids 
and drugs used in the management of influenza were also 
significantly more prescribed to children under five. Pre-
scription of vitamins was comparable in both groups.
Prescription of antibiotics was found to be comparable 
(p = 0.137802) in patients with positive biological con-
firmation, of malaria 69.1% (818/1184) and those with 
Table 4 Treatment regimen for uncomplicated malaria
Anti-malarials Number (%) 95% CI
ASAQ 860 (37.4) 35.4–39.4
QUININE 745 (32.4) 30.5–34.3
AL 388 (16.9) 15.4–18.5
A‑β arteether 91 (4.0) 3.2–4.8
ARTEMETHER inj 56 (2.4) 1.8–3.2
SP 52 (2.3) 1.7–3.0
Quinine + ASAQ 23 (1.0) 0.6–1.5
Other 85 (3.7) 3.0–4.5
Total 2300 (100)
Table 5 Drugs concomitantly prescribed with anti-malarials
Drug groups (N = 2300) Number 
of patients (%) 
[95% CI]
Most frequently co-prescribed drugs in the group (n; %)
Analgesics and NSAIDs 1624 (70.6)
[68.7–72.5]
Paracetamol (1217; 52.9%), Metamizole (282; 12.3%), Aspirin (126; 5.5%), Diclofenac (80; 3.5%), Paraceta‑
mol/Ibuprofen (50; 2.2%), Ibuprofen (32; 1.4%), Tramadol (10; 0.4%)
Antibiotics 1561 (67.9)
[66.0–69.8]
Amoxicillin (416; 18.1%), Metronidazole (303; 13.2%), Cotrimoxazole (266; 11.6%), Gentamicin (197; 
8.6%), Ampicillin (171; 7.4%), Ciprofloxacin (158; 6.9%), Erythromycin (148; 6.4%)
Vitamins 670 (29.1)
[27.3–31.0]
Multivitamins (348; 15.1%), vitamin C (124; 5.4%), Vitamin B1/B6/B12 (123; 5.3%), Vitamin B complex (76; 
3.3%), vitamin B6 (48; 2.1)
Other anti‑infectious drugs 633 (27.5)
[25.7–29.3]
Mebendazole (524; 22.8%), Albendazole (50; 2.2%), Nystatin (29; 1.3%), Pyrantel pamoate (15; 0.7%), 
Clotrimazole (12; 0.5%), Levamisole (9; 0.4%)
Anaemia drugs 210 (9.1)
[8.0–10.3]
Folic acid (68; 3.0%), Nutrisang (34; 1.5%), Hifer (31; 1.3%), VIT B12 (17; 0.7%), vitro z (13; 0.6%) Blood 
transfusion (11; 0.5%)
Rehydration solutions 195 (8.5)
[7.3–9.6]
ORS (91; 4.0%), GLUCOSE SOLUTION (72; 3.1%), Ringer lactate (24; 1.0%), NaCl Solution (15; 0.7%)
Flu drugs 140 (6.1)
[5.1–7.1]
Xylometazoline (74; 3.2%), Temperine (43; 1.9%), Rhinathiol (10; 0.4%); cold gripp (9; 0.4%)
Corticosteroids 130 (5.7)
[4.7–6.6]
Dexamethasone (101; 4.4%), Prednisolone (17; 0.7%), Hydrocortisone (16; 0.7%)
Antiallergics 75 (3.3)
[2.5–4.0]
Promethazine (52; 2.3%), Chlorpheniramine (17; 0.7%), Cetirizine (3; 0.1)
Antispasmodics 70 (3.0)
[2.3–3.7]
Papaverine (43; 1.9%), Butyl scopolamine (27; 1.2%)
Antiemetics 51 (2.2)
[1.6–2.8]
Metoclopramide (28; 1.2%), Ondansetron (22; 1.0%), Domperidone (1; 0.0%)
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negative tests 74.2 (186/252). Surprisingly however, anti-
biotics were significantly less prescribed (p = 0.025078) 
in patients with no biological confirmation of malaria, 
64.4% (549/853) than in patients with positive biological 
confirmation.
Discussion
Despite the use of the same powerful dugs, DRC is still 
heavily affected by malaria and concentrates 10% of all 
deaths related to malaria worldwide, most of whom are 
children under 5 years old. Inappropriate use of drugs in 
the management of this disease may play a significant role 
in this counter performance. This study aimed at assess-
ing the use of drugs in the management of uncomplicated 
malaria in rural and urban health zones and referral hos-
pitals. In each of the 11 provinces of DRC, only those in 
or near the capital cities were included. This is also where 
converge the population fleeing the abuses of armed 
groups. The stratification by province, and health facil-
ity, as well as the consideration of rural and urban aspects 
may contribute to increase the representativeness of our 
sample. In addition, the preponderance of patient aged 
less than 5 year could mean a rash between our sample 
and the population affected by malaria in DRC [9]. It 
is worth to notice the 6.3% of infants under 6  months. 
Malaria was thought to be rare in this age group for vari-
ous reasons [14]. But more and more data suggest that 
malaria may not be as rare as previously thought and 
may be masquerading other severe infectious conditions 
[14] Thus; there is a need to understand more about the 
characteristic of malaria in this age group as well as their 
optimal treatment. The WHO has recognized the infants 
under 12  months [16] as one of the most vulnerable 
population. Use of long-lasting insecticidal nets (LLINs), 
intermittent preventive therapy with SP for infants (IPTi) 
and prompt diagnosis and effective treatment of malaria 
infections [16] have been recommended. For some of 
these infants, especially those weighing less than 5  kg, 
there is a lack of proven treatment options: none of the 
current ACT is approved for infants under 4.5  kg, and 
there are concerns about the safety of quinine in this age 
group [17] and, as shown for AL [18], pharmacokinetics 
of some drugs recommended for other age group, can 
be different in this group, leading to increased exposure 
to these substances. There is still a need for evidence to 
understand more about the best treatment for this vul-
nerable population that represents a non-negligible pro-
portion of the malaria patients.
Malaria treatment was initiated without biological con-
firmation in almost half of the cases. This may results 
in wastage of drugs that should be given to true malaria 
cases [19], unnecessary and avoidable adverse drug reac-
tions (ADR) and delay in the detection of the true illness 
of the patient which can be lethal [20]. Indeed the WHO 
and the Congolese NMCP have recommended biologi-
cal confirmation of malaria by either RDT or microscopy 
before initiation of treatment. However, the performance 
of diagnostic tests prior to treatment is not a guarantee of 
optimal use of anti-malarials. Malaria treatment initiated 
despite negative results in 11% of cases which is in line 
with other studies [21, 22] with a rate of malaria treat-
ment despite negative laboratory testing diagnosis of as 
high as 58% in Nigeria [21]. This inappropriate prescrip-
tion of anti-malarials despite negative results may be 
caused by the assumption of undetectable malaria, lack 
of tools for alternative diagnosis, provider know-how and 
time, the patients demand for drugs [23], lack of trust 
in laboratory results, constancy of anti-malarial supply 
and resistance to change from pre-existing patterns [24]. 
Another issue is the drug prescribed: The recommended 
ACT formulations, ASAQ and AL, were prescribed in 
only half of the cases. Patients below 5  years old were 
more likely to be prescribed ASAQ or quinine whereas 
the older patient received more AL and alpha–beta 
arteether. Currently, ACT is the best choice for manage-
ment of uncomplicated malaria. The demonstrated effi-
cacy and safety of ASAQ [25, 26] and AL [27, 28] have led 
the NMCP of DRC to recommend them [12] for manage-
ment of uncomplicated malaria. On the other hand qui-
nine use in malaria treatment was established before the 
methods for modern clinical trials were developed [29]; 
this drug has a low therapeutic index [17], which means 
an increased risk of dose-related adverse reactions. In 
addition, head to head studies have shown superiority 
of ACT over quinine in the management of uncompli-
cated malaria [30, 31]. Despite these evidences, quinine 
continue to be used (up to 40% in children under 5 years 
old). One of the reasons would be that this drug has been 
used against malaria for a long time. The drug is so popu-
lar that in many areas of DRC that the word quinine has 
Table 6 Concomitant medication in children under 5 years 
old compared to other patients
Drugs < 5 years, 
number (%)
N = 845
≥ 5 years, 
number (%)
N = 1382
p value
Antibiotics 634 (75.0) 876 (63.4) < 0.00001
Antalgics and NSAIDs 631 (74.7) 944 (68.3) 0.001353
Vitamins 245 (29.0) 402 (29.1) 0.962106
Other anti infectious 254 (30.1) 362 (26.2) 0.047849
Anemia drugs 137 (16.2) 68 (4.9) < 0.00001
Rehydration 83 (9.8) 97 (7.0) 0.0185
Flu drugs 74 (8.8) 61 (4.4) 0.000031
Corticosteroids 67 (7.9) 57 (4.1%) 0.000145
Page 6 of 8Ntamabyaliro et al. Malar J  (2018) 17:189 
been included in local languages as a word for any tab-
let. Yet, the widespread usage of quinine may probably be 
playing a role in the low performance of DRC in malaria 
mortality and morbidity. The injectable artemether and 
alpha beta arteether were also used despite they are not 
recommended for uncomplicated malaria and there is 
no WHO prequalified product available [32]. The use of 
these injectable monotherapies in uncomplicated malaria 
may also fuel drug resistance like the oral artemisinin-
based monotherapies (oAMT). Oral monotherapy of 
artesunate, dihydroartemisinin (DHA) and amodiaquine 
were used in 3, 4 and 1 patients, respectively. This seems 
very low, but there is still a concern: the WHO has identi-
fied use of oAMT as one of the major driver of resistance 
to artemisinin and its derivatives [33]. The regulatory 
authority of DRC has responded by withdrawing market-
ing authorization to oAMT [34], but these drugs are still 
prescribed and this raises also the question of the origin 
of these oAMT, their presence in pharmacies and unau-
thorized drug sellers and why they are still prescribed by 
health professionals. Compliance to treatment guidelines 
is a major factor of treatment success [35]. However, pre-
scribers adhered to treatment policy in only half of the 
cases which is in line with findings from other countries 
in Sub-Saharan Africa [6–8]. This may be related to many 
factors like stock-outs, ignorance, the attempt to save 
money, difficulties to change habits or misleading incen-
tives. Better organisation of health facilities and train-
ing of personnel may significantly increase adherence to 
national policy as shown in Uganda [36]. Nevertheless, 
adherence to treatment guidelines by health workers is 
not the end of the story; it is important to take in account 
adherence of the patient to the prescription. Onyango 
et al. have shown that adherence to prescription was very 
low especially in the poorest, less educated and younger 
patients [37]. So when assessing factors related to low 
adherence of prescribers to treatment policy, it is impor-
tant to take in account the adherence of patients to treat-
ment and related factors in order to put in place more 
adapted corrective measures. In addition to anti-malari-
als, the patients received other concomitant medication.
Uncomplicated malaria presents in the form of numer-
ous unspecific signs and symptoms including most of the 
time headaches, fever, and pain which drive the prescrip-
tion of antipyretic drugs, analgesics or NSAIDs. Paracet-
amol was the most prescribed, however, metamizole a 
drug known to induce rare but irreversible agranulocy-
tosis [38, 39] was given to 12.3% of patients. Given this 
risk and considering the multiple alternatives the use of 
metamizole seems inappropriate.
More than 2/3 of patients were prescribed antibiot-
ics. Children blow 5  years old were significantly more 
likely to be prescribed antibiotics, as shown in other 
studies [8, 40]. The lack of confirmation of malaria or 
negative results are among the drivers of antibiotic co-
prescription with anti-malarials [41] But, surprisingly, 
prescription of antibiotics was comparable in patient 
with positive and negative parasitological exams. Patient 
for which confirmation of malaria was not sought were 
prescribed rather less antibiotics. Some Congolese pre-
scribers assume inexplicably that better management of 
malaria requires addition of antibiotics to anti-malarials. 
Whether this is a misunderstanding of the recommen-
dation to combine quinine with clindamycin or doxycy-
cline, or no is not known. Nevertheless, this remains an 
issue that needs an assessment of extent and determi-
nants in Congolese settings because it may be part of the 
irrational use of antibiotics which is common especially 
in developing countries and a major contributor to bacte-
rial resistance [8, 42]. Considering the high prevalence of 
malaria in DRC and the high prescription of antibiotics 
for malaria, management of malaria may be threatening 
treatment of bacterial infection and this can cause signifi-
cant problems to patients and health systems.
Vitamins, mostly multivitamins were prescribed to 
29.1% of patients, without an indication mentioned in 
the files. There was no significant difference in prescrip-
tion to children under-five compared to other patients. 
Neither the WHO guidelines nor the national guidelines 
recommend usage of vitamins in the management of 
malaria. Some studies have speculated that the antioxi-
dant effect of vitamins, especially vitamin C and E, may 
reduce efficacy of artemisinin derivatives [43]. The same 
concern may be evoked regarding the use of iron whose 
supplementation in children has been shown to increase 
susceptibility to malaria [44, 45]. The effect of iron sup-
plementation on the efficacy of ACT has not been 
assessed; however, a study in Malawi [46] showed reduc-
tion in efficacy of sulfadoxine-pyrimethamine in children 
receiving concomitantly SP and iron supplementation. 
Other studies [47, 48] has shown no beneficial effect 
iron supplementation during malaria treatment. In DRC 
where, 60% of children aged 6–59 months are affected by 
anaemia [9], these interactions need to be more assessed 
in order to propose more efficient strategies.
Blood transfusion in the context of management of 
malaria is used to improve oxygen delivery to tissue, due 
to severe anaemia. Eleven children under five received 
blood transfusion and the recorded indication was just 
anaemia. In severe malaria, blood transfusion may be 
necessary, but benefits of this procedure need to be 
weighed against risks of transmission of serious infec-
tious diseases (HIV, hepatitis B) severe immunologic 
reactions, volume overload, hyperkalaemia [49]. Trans-
fusions are necessary when the level of haemoglobin is 
so low that it is not tolerated and that may define severe 
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malaria [29]. These 11 transfusions may be related to 
misclassification of complicated malaria cases as uncom-
plicated, or to the numerous unnecessary transfusions 
given to ambulatory patients.
Conclusion
DRC is still heavily affected by malaria despite the effec-
tiveness of available tools to control this potentially lethal 
disease. Inappropriate use of those tools, namely medi-
cines still hampers better control of the disease. Half of 
the patients receive malaria treatment with no diagnos-
tic confirmation and adherence to treatment guidelines 
is low. Quinine, which is no more recommended for 
uncomplicated malaria is still widely used. In addition, 
the management of uncomplicated malaria is character-
ized by polypharmacy, mostly in children below 5 years 
old. Dangerous analgesics like metamisole are used. Anti-
biotics and other drugs, like vitamins, anaemia drugs and 
corticosteroids are prescribed, most of the time without 
an indication. The massive use of antibiotics raises the 
concerning question that management of uncomplicated 
malaria in DRC may be one of the drivers of selection 
of resistant bacteria which is a serious threat to public 
health. All these practices may be threatening the suc-
cess of the control of malaria in DRC. There is a need 
to train all stakeholders in the proper management of 
uncomplicated malaria and make available all diagnos-
tic tools, especially RDTs and the recommended drugs. 
The withdrawal of the non-recommended drug from the 
marked will also improve the management of uncompli-
cated malaria. The determinants of all these situations 
need to be assessed in order to formulate more accurate 
recommendations.
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